Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Cash from Financing (TTM): 136.74M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 136.74M |
December 31, 2023 | 136.39M |
September 30, 2023 | 181.87M |
June 30, 2023 | 41.14M |
March 31, 2023 | 51.83M |
December 31, 2022 | 52.10M |
September 30, 2022 | 19.97M |
Date | Value |
---|---|
June 30, 2022 | 50.05M |
March 31, 2022 | 38.98M |
December 31, 2021 | 39.08M |
September 30, 2021 | 28.50M |
June 30, 2021 | 272.70M |
March 31, 2021 | 273.04M |
December 31, 2020 | 291.06M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
19.97M
Minimum
Sep 2022
291.06M
Maximum
Dec 2020
115.25M
Average
51.97M
Median
Cash from Financing (TTM) Benchmarks
Aquestive Therapeutics Inc | 94.92M |
Lifecore Biomedical Inc | 56.06M |
Relmada Therapeutics Inc | 0.1233M |
ACADIA Pharmaceuticals Inc | 24.71M |
Cyclacel Pharmaceuticals Inc | 0.848M |